Nefazodone

Its place among antidepressants

Monica Cyr, Candace Brown

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, adverse effects, and drug interactions of nefazodone, as well as to determine its place among currently available antidepressants. DATA SOURCES: A search of European and American literature using EMBASE and MEDLINE was completed. Nefazodone was the search term. DATA SYNTHESIS: Nefazodone is an antidepressant that blocks serotonin type 2 (5-HT2) receptors in addition to inhibiting the reuptake of serotonin and norepinephrine. In double-blind, placebo-controlled studies, nefazodone demonstrates antidepressant activity at dosages ranging from 400 to 600 mg/d. Sedation, dry mouth, nausea, and dizziness are the more common adverse effects of nefazodone. Nefazodone, an analog of trazodone, has not been associated with priapism at this time, and may have fewer sexual adverse effects than other antidepressants. More studies are needed to determine the potential role of nefazodone in treating anxiety, pain, and premenstrual syndrome. STUDY SELECTION: Only double- blind, placebo-controlled studies designed to establish the efficacy of nefazodone as an antidepressant were reviewed. CONCLUSIONS: Based on placebo- controlled, double-blind, comparative trials, nefazodone demonstrates greater efficacy than placebo, and equivalent efficacy to imipramine. Somnolence, dry mouth, nausea, dizziness, and constipation are the most common adverse effects. Nefazodone appears to have a milder adverse effect profile than the tricyclic antidepressants, causes fewer sexual dysfunctions than the serotonin selective reuptake inhibitors, and may cause less dizziness titan trazodone. Nefazodone at dosages of at least 300 mg/d provides another option for the treatment of depression.

Original languageEnglish (US)
Pages (from-to)1006-1012
Number of pages7
JournalAnnals of Pharmacotherapy
Volume30
Issue number9
DOIs
StatePublished - Jan 1 1996

Fingerprint

Antidepressive Agents
Dizziness
Placebos
Trazodone
Nausea
Mouth
nefazodone
Serotonin 5-HT2 Receptors
Saturn
Priapism
Premenstrual Syndrome
Imipramine
Tricyclic Antidepressive Agents
Serotonin Uptake Inhibitors
Constipation
Drug Interactions
MEDLINE
Serotonin
Norepinephrine
Anxiety

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Nefazodone : Its place among antidepressants. / Cyr, Monica; Brown, Candace.

In: Annals of Pharmacotherapy, Vol. 30, No. 9, 01.01.1996, p. 1006-1012.

Research output: Contribution to journalReview article

Cyr, Monica ; Brown, Candace. / Nefazodone : Its place among antidepressants. In: Annals of Pharmacotherapy. 1996 ; Vol. 30, No. 9. pp. 1006-1012.
@article{00ac2630349a4f76866cc9bb31eafd95,
title = "Nefazodone: Its place among antidepressants",
abstract = "OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, adverse effects, and drug interactions of nefazodone, as well as to determine its place among currently available antidepressants. DATA SOURCES: A search of European and American literature using EMBASE and MEDLINE was completed. Nefazodone was the search term. DATA SYNTHESIS: Nefazodone is an antidepressant that blocks serotonin type 2 (5-HT2) receptors in addition to inhibiting the reuptake of serotonin and norepinephrine. In double-blind, placebo-controlled studies, nefazodone demonstrates antidepressant activity at dosages ranging from 400 to 600 mg/d. Sedation, dry mouth, nausea, and dizziness are the more common adverse effects of nefazodone. Nefazodone, an analog of trazodone, has not been associated with priapism at this time, and may have fewer sexual adverse effects than other antidepressants. More studies are needed to determine the potential role of nefazodone in treating anxiety, pain, and premenstrual syndrome. STUDY SELECTION: Only double- blind, placebo-controlled studies designed to establish the efficacy of nefazodone as an antidepressant were reviewed. CONCLUSIONS: Based on placebo- controlled, double-blind, comparative trials, nefazodone demonstrates greater efficacy than placebo, and equivalent efficacy to imipramine. Somnolence, dry mouth, nausea, dizziness, and constipation are the most common adverse effects. Nefazodone appears to have a milder adverse effect profile than the tricyclic antidepressants, causes fewer sexual dysfunctions than the serotonin selective reuptake inhibitors, and may cause less dizziness titan trazodone. Nefazodone at dosages of at least 300 mg/d provides another option for the treatment of depression.",
author = "Monica Cyr and Candace Brown",
year = "1996",
month = "1",
day = "1",
doi = "10.1177/106002809603000916",
language = "English (US)",
volume = "30",
pages = "1006--1012",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "9",

}

TY - JOUR

T1 - Nefazodone

T2 - Its place among antidepressants

AU - Cyr, Monica

AU - Brown, Candace

PY - 1996/1/1

Y1 - 1996/1/1

N2 - OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, adverse effects, and drug interactions of nefazodone, as well as to determine its place among currently available antidepressants. DATA SOURCES: A search of European and American literature using EMBASE and MEDLINE was completed. Nefazodone was the search term. DATA SYNTHESIS: Nefazodone is an antidepressant that blocks serotonin type 2 (5-HT2) receptors in addition to inhibiting the reuptake of serotonin and norepinephrine. In double-blind, placebo-controlled studies, nefazodone demonstrates antidepressant activity at dosages ranging from 400 to 600 mg/d. Sedation, dry mouth, nausea, and dizziness are the more common adverse effects of nefazodone. Nefazodone, an analog of trazodone, has not been associated with priapism at this time, and may have fewer sexual adverse effects than other antidepressants. More studies are needed to determine the potential role of nefazodone in treating anxiety, pain, and premenstrual syndrome. STUDY SELECTION: Only double- blind, placebo-controlled studies designed to establish the efficacy of nefazodone as an antidepressant were reviewed. CONCLUSIONS: Based on placebo- controlled, double-blind, comparative trials, nefazodone demonstrates greater efficacy than placebo, and equivalent efficacy to imipramine. Somnolence, dry mouth, nausea, dizziness, and constipation are the most common adverse effects. Nefazodone appears to have a milder adverse effect profile than the tricyclic antidepressants, causes fewer sexual dysfunctions than the serotonin selective reuptake inhibitors, and may cause less dizziness titan trazodone. Nefazodone at dosages of at least 300 mg/d provides another option for the treatment of depression.

AB - OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, adverse effects, and drug interactions of nefazodone, as well as to determine its place among currently available antidepressants. DATA SOURCES: A search of European and American literature using EMBASE and MEDLINE was completed. Nefazodone was the search term. DATA SYNTHESIS: Nefazodone is an antidepressant that blocks serotonin type 2 (5-HT2) receptors in addition to inhibiting the reuptake of serotonin and norepinephrine. In double-blind, placebo-controlled studies, nefazodone demonstrates antidepressant activity at dosages ranging from 400 to 600 mg/d. Sedation, dry mouth, nausea, and dizziness are the more common adverse effects of nefazodone. Nefazodone, an analog of trazodone, has not been associated with priapism at this time, and may have fewer sexual adverse effects than other antidepressants. More studies are needed to determine the potential role of nefazodone in treating anxiety, pain, and premenstrual syndrome. STUDY SELECTION: Only double- blind, placebo-controlled studies designed to establish the efficacy of nefazodone as an antidepressant were reviewed. CONCLUSIONS: Based on placebo- controlled, double-blind, comparative trials, nefazodone demonstrates greater efficacy than placebo, and equivalent efficacy to imipramine. Somnolence, dry mouth, nausea, dizziness, and constipation are the most common adverse effects. Nefazodone appears to have a milder adverse effect profile than the tricyclic antidepressants, causes fewer sexual dysfunctions than the serotonin selective reuptake inhibitors, and may cause less dizziness titan trazodone. Nefazodone at dosages of at least 300 mg/d provides another option for the treatment of depression.

UR - http://www.scopus.com/inward/record.url?scp=0029793608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029793608&partnerID=8YFLogxK

U2 - 10.1177/106002809603000916

DO - 10.1177/106002809603000916

M3 - Review article

VL - 30

SP - 1006

EP - 1012

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 9

ER -